AHA: Dronedarone Detrimental for Certain A-Fib Patients

Counter to hypothesis, agent may cause major vascular events

MONDAY, Nov. 14 (HealthDay News) -- Dronedarone, an antiarrhythmic agent that stabilizes patients with intermittent atrial fibrillation, appears to increase the risk of hospitalization and death in certain patients with permanent atrial fibrillation, according to a study published online Nov. 14 in the New England Journal of Medicine to coincide with presentation at the American Heart Association's Scientific Sessions 2011, held from Nov. 12 to 16 in Orlando, Fla.

Stuart J. Connolly, M.D., of the Population Health Research Institute in Hamilton, Canada, and colleagues assigned 3,236 patients aged 65 and older with a six-month or longer history of permanent atrial fibrillation and risk factors for major vascular events to either dronedarone or placebo. The authors sought to test their hypothesis that the drug would reduce major vascular events in this patient population.

The study was stopped early due to safety concerns. The researchers found that stroke, myocardial infarction, systemic embolism, or death from cardiovascular causes occurred in 43 patients receiving dronedarone, compared with 19 patients receiving placebo. Death due to cardiovascular causes occurred in 21 patients from the treatment group and 10 patients from the placebo group.

"Dronedarone increased the rates of stroke, heart failure, and death from cardiovascular causes in patients with permanent atrial fibrillation and risk factors for vascular events. Our data show that dronedarone is hazardous in such patients," the authors write.

The study was funded in part by Sanofi-Aventis; several authors disclosed financial relationships with pharmaceutical companies, including Sanofi-Aventis.

Full Text
More Information

Copyright © 2011 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles

Debunking Three Rape Myths
Journal of Forensic Nursing, October/December 2014
Expires: 12/31/2016 CE:2.5 $24.95

Drug updates and approvals: 2014 in review
The Nurse Practitioner, 13December 2014
Expires: 12/31/2016 CE:3 $27.95

Can Food Processing Enhance Cancer Protection?
Nutrition Today, September/October 2014
Expires: 10/31/2016 CE:2 $21.95

More CE Articles

Subscribe to Recommended CE

Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events